The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III NSCLC (TRAILBLAZER): Efficacy, safety and feasibility of surgical conversion outcomes from a proof-of-concept, phase 2 trial.
 
Yi-Long Wu
Honoraria - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)
 
Qing Zhou
No Relationships to Disclose
 
Yi Pan
No Relationships to Disclose
 
Xue-Ning Yang
No Relationships to Disclose
 
Yanqiu Zhao
No Relationships to Disclose
 
Guang Han
No Relationships to Disclose
 
Qingsong Pang
No Relationships to Disclose
 
Zhenfa Zhang
No Relationships to Disclose
 
Qifeng Wang
No Relationships to Disclose
 
Jun Yao
No Relationships to Disclose
 
Hui Wang
No Relationships to Disclose
 
Weihua Yang
No Relationships to Disclose
 
Baogang Liu
No Relationships to Disclose
 
Qixun Chen
No Relationships to Disclose
 
Xianghui Du
No Relationships to Disclose
 
Kaican Cai
No Relationships to Disclose
 
Baosheng Li
No Relationships to Disclose
 
Xiao Li
Employment - Hengrui Pharmaceutical
 
Li Song
Employment - Hengrui Pharmaceutical
 
Wei Shi
Employment - Hengrui Pharmaceutical